Steinkraus V, Nose M, Mensing H, Körner C
Abteilung Allgemeine Pharmakologie, Universitäts-Krankenhaus Eppendorf, Hamburg, F.R.G.
Br J Dermatol. 1990 Aug;123(2):163-70. doi: 10.1111/j.1365-2133.1990.tb01843.x.
The existence of beta-adrenoceptors on intact cells of the human malignant melanoma cell line A-375 was investigated using the binding properties of the tritiated radioligand (-)-[3H]CGP-12177, a hydrophilic non-selective beta-adrenoceptor antagonist. Displacement experiments of the radioligand from its binding site were performed with antagonists and agonists to determine the beta-adrenoceptor subtype selectivity. The binding of (-)-[3H]CGP-12177 was saturable, of high affinity (KD = 0.025 nmol/l, n = 12) and was rapid and readily reversible. The maximal number of binding sites (Bmax) was 33.5 +/- 1.9 fmol/10(7) cells or 2018 +/- 114 receptors per cell. beta-adrenoceptor antagonists inhibited binding of the radioligand with monophasic displacement curves. IC50 values were (nmol/l): propranolol (non-selective) 2.82, alprenolol (non-selective) 2.0, ICI 118,551 (beta 2-selective) 3.5 and bisoprolol (beta 1-selective) 2200. Agonists inhibited binding in the order of potency of isoprenaline greater than adrenaline greater than noradrenaline. It is concluded that cells of the melanoma cell line A-375 contain a homogeneous population of beta 2-adrenoceptors.
利用亲水性非选择性β-肾上腺素能受体拮抗剂氚标记放射性配体(-)-[3H]CGP-12177的结合特性,研究了人恶性黑色素瘤细胞系A-375完整细胞上β-肾上腺素能受体的存在情况。用拮抗剂和激动剂进行放射性配体从其结合位点的置换实验,以确定β-肾上腺素能受体亚型的选择性。(-)-[3H]CGP-12177的结合具有饱和性、高亲和力(KD = 0.025 nmol/l,n = 12),且快速且易于逆转。结合位点的最大数量(Bmax)为33.5±1.9 fmol/10(7)个细胞或每个细胞2018±114个受体。β-肾上腺素能受体拮抗剂以单相置换曲线抑制放射性配体的结合。IC50值(nmol/l)分别为:普萘洛尔(非选择性)2.82、阿普洛尔(非选择性)2.0、ICI 118,551(β2选择性)3.5和比索洛尔(β1选择性)2200。激动剂抑制结合的效力顺序为异丙肾上腺素>肾上腺素>去甲肾上腺素。结论是黑色素瘤细胞系A-375的细胞含有同质的β2-肾上腺素能受体群体。